Czech National Bank Has $5.37 Million Holdings in Labcorp Holdings Inc. $LH

Czech National Bank grew its stake in Labcorp Holdings Inc. (NYSE:LH) by 6.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 20,459 shares of the medical research company’s stock after buying an additional 1,304 shares during the period. Czech National Bank’s holdings in Labcorp were worth $5,371,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in LH. Golden State Wealth Management LLC lifted its position in shares of Labcorp by 88.1% in the first quarter. Golden State Wealth Management LLC now owns 111 shares of the medical research company’s stock worth $26,000 after buying an additional 52 shares during the last quarter. North Capital Inc. acquired a new stake in shares of Labcorp in the first quarter worth about $27,000. TruNorth Capital Management LLC acquired a new stake in shares of Labcorp in the first quarter worth about $28,000. Larson Financial Group LLC lifted its position in shares of Labcorp by 140.4% in the first quarter. Larson Financial Group LLC now owns 125 shares of the medical research company’s stock worth $29,000 after buying an additional 73 shares during the last quarter. Finally, Financial Gravity Asset Management Inc. acquired a new stake in shares of Labcorp in the first quarter worth about $31,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Trading Up 0.4%

Shares of LH opened at $277.20 on Friday. Labcorp Holdings Inc. has a 12-month low of $209.38 and a 12-month high of $283.47. The company has a quick ratio of 1.32, a current ratio of 1.50 and a debt-to-equity ratio of 0.61. The firm has a market capitalization of $23.04 billion, a price-to-earnings ratio of 30.60, a P/E/G ratio of 1.77 and a beta of 0.85. The stock’s 50-day moving average price is $267.34 and its 200 day moving average price is $251.79.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $4.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.14 by $0.21. The firm had revenue of $3.53 billion for the quarter, compared to analyst estimates of $3.49 billion. Labcorp had a return on equity of 15.45% and a net margin of 5.66%.The company’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.94 earnings per share. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS. As a group, research analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Thursday, August 28th were issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend was Thursday, August 28th. Labcorp’s payout ratio is presently 31.79%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on LH shares. Robert W. Baird set a $311.00 price objective on Labcorp in a research note on Monday, August 25th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. HSBC lowered Labcorp from a “buy” rating to a “hold” rating and set a $260.00 price objective on the stock. in a research note on Thursday, July 10th. Barclays reiterated a “cautious” rating on shares of Labcorp in a research note on Wednesday, June 25th. Finally, Morgan Stanley lifted their price objective on Labcorp from $283.00 to $306.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Nine investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $290.33.

Insider Buying and Selling

In other Labcorp news, CEO Adam H. Schechter sold 5,643 shares of Labcorp stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $266.78, for a total transaction of $1,505,439.54. Following the sale, the chief executive officer directly owned 93,319 shares of the company’s stock, valued at approximately $24,895,642.82. The trade was a 5.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Dwight Gary Gilliland sold 2,000 shares of Labcorp stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $264.95, for a total value of $529,900.00. Following the sale, the director directly owned 6,656 shares in the company, valued at $1,763,507.20. The trade was a 23.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,546 shares of company stock valued at $4,207,192 over the last ninety days. Company insiders own 0.84% of the company’s stock.

Labcorp Company Profile

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.